Highlights Evoke Pharma, Inc.

Equities

EVOK

US30049G2030

Market Closed - Nasdaq Other stock markets 03:49:09 2024-04-29 pm EDT			5-day change	1st Jan Change
0.44 ^USD	-3.93%		-3.30%	-58.11%

Apr. 24	Transcript : Evoke Pharma, Inc. - Special Call
Mar. 21	Evoke Pharma, Inc. Announces Board Changes as of March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Evoke Pharma, Inc. Provides Earnings Guidance for 2024	Mar. 14	CI
Evoke Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Evoke Pharma Says FDA Lists Latest US Patent for Gimoti in Orange Book	Nov. 27	MT
Evoke Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Evoke Pharma, Inc. Provides Summary of Real-World Data on the Positive Impact of GIMOTI	Nov. 01	CI
Evoke Pharma, Inc. Enters into Sixth Amendment to Lease with SB Corporate Centre III-IV, LLC	23-10-12	CI
Evoke Pharma, Inc. Receives Notice of Allowance from U.S. Patent and Trademark Office for GIMOTI	23-09-14	CI
Evoke Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Evoke Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Evoke Pharma, Inc. Announces United States Patent and Trademark Office Issues US Patent No. 11,628,150 Under the Title Nasal Formulations of Metoclopramide	23-04-20	CI
Evoke Pharma Says US Patent and Trademark Office Grants Formulation Patent Covering GIMOTI Nasal Spray	23-04-20	MT
Evoke Pharma, Inc. Provides Revenue Guidance for 2023	23-03-21	CI
Earnings Flash (EVOK) EVOKE PHARMA Posts Q4 Revenue $796,000	23-03-21	MT
Evoke Pharma Says Joint Stipulation of Dismissal Filed in Gimoti Patent Infringement Case Involving Teva Pharmaceuticals	23-01-30	MT
Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy Annual Meeting 2023	23-01-18	CI
Evoke Pharma Receives Notice of Allowance for US Patent Application for Gimoti; Shares Rise	22-11-30	MT
Evoke Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
Evoke Pharma, Inc. announces United States Patent and Trademark Office Issues Notice of Allowance for the its Product, GIMOTI® (Metoclopramide) Nasal Spray	22-09-20	CI
Evoke Pharma, Inc. and Eversana Expand Patient Access to Gimoti with New Telehealth Solution	22-08-16	CI
Evoke Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Evoke Pharma, Inc.

Equities

EVOK

US30049G2030

Highlights

Filters